STAAR Surgical

STAAR Surgical Co. engages in the development, manufacture, production, marketing, and sale of implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. It specializes in refractive and cataract solutions. Its products include intraocular lens and implantable collamer lens. The company was founded in 1982 and is headquartered in Lake Forest, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

STAAR Surgical reports robust Q4 performance and eyes U.S. growth

STAAR Surgical's Q4 2022 earnings call highlighted strong performance, growth opportunities in key markets, and strategic investments for future success. Despite challenges in China, the company remains optimistic about market recovery and growth prospects. With a focus on EVO lens adoption and increased investments, STAAR is well-positioned for continued growth and market expansion.

STAAR Surgical excels in Q1 with strong global sales growth

STAAR Surgical's Q1 2023 earnings call highlighted robust global sales growth, positive market reception, and strategic investments for future expansion. The company aims to strengthen its market position through targeted growth strategies and operational enhancements.

STAAR Surgical reports record Q2 sales, eyes global expansion

STAAR Surgical's Q2 2023 performance showcased record sales and growth, driven by the EVO family of ICLs.
The company's strong presence in APAC, particularly China, and confidence in high-growth outlook are notable.
Challenges include market declines and pricing dynamics, but opportunities lie in global expansion and strategic initiatives.
Balancing growth and profitability remains a focus, with ongoing efforts to enhance market presence and address challenges.

STAAR Surgical reports resilient Q3 performance amidst market challenges

STAAR Surgical's Q3 2023 performance reflects continued growth in ICL sales despite challenges.
The company is navigating macroeconomic headwinds while focusing on market-building initiatives.
Despite a decline in operating income, STAAR remains confident in its growth prospects.
STAAR's strategic focus on new products and market expansion positions it for future success.

STAAR Surgical posts robust Q4 results, eyes global expansion opportunities

STAAR Surgical's strong financial performance and strategic initiatives position the company for continued growth and market leadership.
Challenges from market competition and macroeconomic factors require careful navigation, but opportunities in expanding markets and operational enhancements offer avenues for growth.
With a focus on innovation, profitability, and global expansion, STAAR is poised to capitalize on market trends and drive sustainable growth in the coming years.

STAAR Surgical surpasses Q1 sales targets, eyes global expansion

STAAR Surgical's Q1 2024 performance exceeded expectations, driven by strong global sales growth and strategic milestones. Challenges include addressing discrepancies in sales and unit growth. The company is poised to capitalize on opportunities in China, surgeon training, and international expansion.

STAAR Surgical posts robust Q2 results, eyes global expansion

STAAR Surgical's Q2 2024 performance reflects strong sales growth, improved profitability, and a positive outlook for fiscal 2024.
The company's strategic strengths in global market expansion and innovation position it well for future growth and achieving long-term sales targets.
Challenges in managing operating expenses and sustaining growth rates in key markets require continued strategic focus and operational efficiency.
Opportunities in expanding market presence, driving innovation, and leveraging financial strength present avenues for sustained growth and market leadership.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

STAAR Surgical Co. engages in the design, development, manufacture, and sale of ophthalmic surgical products. The firm offers implantable lenses for the eye and accessory delivery systems. Its products include refractive and cataract solutions through the Collamer brand. The company was founded in 1982 and is headquartered in Lake Forest, CA.

Here's why it's not too late to go long on this eye surgery lens firm.

Is STAAR Surgical a Buy?

Align Technology

Molina Healthcare

You probably haven't heard of these companies, but they're winners.

3 Outside-the-Box Healthcare Stocks That Could Set You Up for Life

ABIOMED

Teladoc

I've been waiting to buy these stocks at a better price. Now might just be the time.

Buy These 3 Breakout Healthcare Stocks if There's a Sell-Off or Correction

Johnson & Johnson

These companies are perfect for investors with a long time horizon.

Got $2,800? Invest in Your Family's Future With These 2 Stocks

No news is good news for this healthcare company.

Why STAAR Surgical Company Stock Is Soaring Today

Staar Surgical manufactures and markets implantable collamer lenses for myopia or presbyopia. The company's shares have performed impressively in recent months - reaching highs of $127 - but have fallen to $104 during the recent bear market.

Staar Surgical: Recent Bull Run Is Over, But Buying The Dip Advisable

STAAR Surgical Company (STAA) CEO Caren Mason on Q4 2020 Results - Earnings Call Transcript

Staar Surgical (STAA) delivered earnings and revenue surprises of 55.56% and 1.32%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Staar Surgical (STAA) Q4 Earnings and Revenues Top Estimates

Shares of Staar Surgical (NASDAQ:STAA) moved lower in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share increased 16.67% over the past year to $0.14, which beat the estimate of $0.02.

Recap: Staar Surgical Q4 Earnings

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today reported financial results for the fourth quarter and fiscal year ended January 1, 2021. Fourth Quarter 2020 Overview Net Sales of $46.0 Million Up 18% from the Prior Year Quarter ICL Sales of $39.8 Million Up 20% from the Prior Year Quarter ICL Units Up 13% from the Prior Year Quarter Gross Margin at

STAAR Surgical Reports Fourth Quarter and Full Year 2020 Results

There isn't much for long-term investors to worry about.

Why STAAR Surgical Stock Is Dropping Today

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today announced that it will release financial results for the fourth quarter and fiscal year ended January 1, 2021 on Wednesday, February 24, 2021 after the market close. STAAR will host a conference call and webcast on Wednesday, February 24 at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial

STAAR Surgical to Report Fourth Quarter and Fiscal Year Results on February 24, 2021

The stock price of STAAR Surgical Company (NASDAQ: STAA) increased by 16.38% as it went from a previous close of$89.77 to $104.47 on Tuesday, January 26. This is why it happened.

STAA Stock Price Increased 16.38%: Why It Happened

Both companies are set to join new market indexes.

Why STAAR Surgical and Prestige Consumer Healthcare Stocks Jumped Today

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today announced the appointments of Elizabeth Yeu, M.D., Partner, Virginia Eye Consultants, and K. Peony Yu, M.D., retired Chief Medical Officer, FibroGen Inc., to its Board of Directors, effective January 21, 2021. “The addition of Dr. Elizabeth Yeu and Dr. K. Peony Yu to our Board of Directors illustrates

Elizabeth Yeu, M.D. and K. Peony Yu, M.D.

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today provided preliminary results for the fourth quarter and fiscal year ended January 1, 2021. The Company expects total net sales for the fourth quarter to be approximately $46 million and full year sales to be approximately $163 million. GAAP earnings per share is expected to be approximately $0.06 for t

STAAR Surgical Announces Preliminary Fourth Quarter and Full Year 2020 Results

BioLife Solutions

TG Therapeutics

Despite MedTech industry's bright prospects in 2021, investors should be wary of stocks like BLFS, STAA and TGTX, given their unfavorable Zacks Rank and weak fundamentals.

3 Soaring MedTech Stocks That Might Lose Ground in 2021

STAAR Surgical manufactures and sells implantable collamer lenses (ICLs) for patients suffering from myopia or presbyopia. The company only makes ~3.5% in the US market and its largest market shares are in APAC - but STAAR is chasing an approval for its latest products in US.

STAAR Surgical: Peak Share Price Suggests Caution, But Long-Term Growth Story Is Persuasive

Staar Surgical (STAA) delivered earnings and revenue surprises of 55.56% and 8.48%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Staar Surgical (STAA) Tops Q3 Earnings and Revenue Estimates

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today announced the initial commercialization of its EVO Viva™ presbyopia correcting lens including the first patient implant. “The first patient received his EVO Viva lenses on October 23 in Belgium from Dr. Erik Mertens, and we are delighted to hear from Dr. Mertens that the patient is quite happy with his

STAAR Surgical Begins Commercialization of EVO Viva™ Presbyopia Correcting Lens

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today reported financial results for the third quarter ended October 2, 2020. Third Quarter 2020 Overview Record Quarterly Net Sales of $47.1 Million Up 21% from the Prior Year Quarter Record Quarterly ICL Sales of $41.5 Million Up 23% from the Prior Year Quarter Record Quarterly ICL Units, Up 25% from the P

STAAR Surgical Reports Third Quarter 2020 Results

Staar Surgical (STAA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Staar Surgical (STAA) to Report a Decline in Earnings: What to Look Out for

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today announced that it will release financial results for the third quarter ended October 2, 2020 on Wednesday, November 4, 2020 after the market close. STAAR will host a conference call and webcast on Wednesday, November 4 at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and operat

STAAR Surgical to Report Third Quarter Results on November 4, 2020

New York, New York--(Newsfile Corp. - October 19, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Staar Surgical Company (NASDAQ: STAA) ("Staar Surgical") between February 26, 2020 and August 10, 2020. You are hereby notified that a securities class action lawsuit has been commenced in the the United States District Court for the Central District of California. To...

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Staar Surgical Company of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 19, 2020 - STAA

New York, New York--(Newsfile Corp. - October 19, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of STAAR Surgical Company (NASDAQ: STAA) between February 26, 2020 and August 10, 2020, inclusive (the "Class Period") of the important October 19, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for STAAR investors under the federal securities laws.To join the STAAR class action,...

News for STAAR Surgical Stock (STAA)